🇺🇸 ABT-333 in United States

72 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 72

Most-reported reactions

1. Hyperbilirubinaemia — 12 reports (16.67%)
2. Anaemia — 11 reports (15.28%)
3. Jaundice — 10 reports (13.89%)
4. Dyspnoea — 6 reports (8.33%)
5. Malaise — 6 reports (8.33%)
6. Nausea — 6 reports (8.33%)
7. Renal Impairment — 6 reports (8.33%)
8. Blood Bilirubin Increased — 5 reports (6.94%)
9. Chest Pain — 5 reports (6.94%)
10. Diarrhoea — 5 reports (6.94%)

Source database →

Frequently asked questions

Is ABT-333 approved in United States?

ABT-333 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ABT-333 in United States?

AbbVie (prior sponsor, Abbott) is the originator. The local marketing authorisation holder may differ — check the official source linked above.